皮肤鳞状细胞癌临床亚型的肿瘤与免疫微环境差异综合图谱
研究对211例cSCC(含37例免疫抑制患者)进行基因组、转录组和免疫组化分析,发现免疫抑制患者瘤周基质B细胞缺失,记忆B细胞样群体丰富与预后较好相关;非头颈部cSCC突变负荷较低且上皮-间质转化上调,与免疫检查点抑制反应较差相关。
要点
- 免疫抑制cSCC患者瘤周基质B细胞缺失,记忆B细胞样群体丰富与预后较好相关。
- 免疫抑制与免疫正常cSCC间遗传变异、突变负荷及突变特征无差异。
- 非头颈部cSCC突变负荷较低且上皮-间质转化上调,与免疫检查点抑制反应较差相关。
核心结论
- cSCC的临床行为差异与肿瘤及宿主免疫因素相关,具有预后判断、治疗预测和新型抗癌疗法识别的转化应用价值。
研究设计与样本
- 对211例cSCC肿瘤(包括37例来自免疫抑制患者的cSCC)进行基因组、转录组和免疫组化特征分析。
主要发现
- 免疫抑制患者的cSCC与免疫正常患者相比,瘤周基质中缺乏B细胞。
- 瘤周基质中丰富的记忆B细胞样群体与所有患者(免疫正常和免疫抑制)以及仅免疫正常患者的较好预后相关。
- 免疫正常与免疫抑制患者的cSCC之间未观察到遗传变异、肿瘤突变负荷或突变特征的差异。
- 非头颈部原发部位的cSCC与头颈部cSCC相比,肿瘤突变负荷较低且上皮-间质转化程序上调。
- 上皮-间质转化程序上调与较差的生存相关,且肿瘤突变负荷较低和上皮-间质转化上调均与对免疫检查点抑制的较差反应相关。
关键数值与推荐
- 免疫抑制患者cSCC瘤周基质B细胞缺乏(与免疫正常患者相比)。
- 瘤周基质记忆B细胞样群体丰富与较好预后相关(所有患者及仅免疫正常患者)。
- 免疫正常与免疫抑制患者cSCC间遗传变异、肿瘤突变负荷及突变特征无差异。
- 非头颈部cSCC较头颈部cSCC肿瘤突变负荷较低且上皮-间质转化程序上调。
临床怎么用
- 瘤周基质记忆B细胞样群体丰富可用于cSCC预后判断。
- 肿瘤突变负荷较低和上皮-间质转化上调与非头颈部cSCC对免疫检查点抑制反应较差相关。
- 免疫抑制与免疫正常cSCC生存差异可能与非肿瘤基因组因素(宿主免疫应答差异)相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous squamous cell carcinomas (cSCCs) are the second most diagnosed skin cancer worldwide; however, little is known about the pathobiological factors that contribute to the diverse clinical outcomes seen. OBJECTIVES: To profile cSCCs comprehensively and identify the pathological processes that contribute to the disparities seen in their clinical behaviour. METHODS: We characterized the genomic, transcriptomic and immunohistochemical profiles of 211 cSCC tumours, including 37 cSCCs from immunocompromised patients. RESULTS: cSCCs from immunocompromised patients were characterized by a lack of B cells in the peritumoral stroma compared with immunocompetent patients. Further, an abundance of a memory B-cell-like population in the peritumoral stroma was associated with a better prognosis in all patients (immunocompetent and immunocompromised), as well as only immunocompetent patients. No differences in genetic -variants, tumour mutational burden or mutational signatures were observed between cSCCs from immunocompetent and immunocompromised patients. Thus, differences in survival between cSCCs from immunocompromised patients and immunocompetent patients are not likely to be driven by tumour genomic factors, but may be associated with differential host immune response. cSCC not from a primary head and neck site had lower tumour mutational burden and exhibited upregulation of the epithelial-mesenchymal transition programme compared with head and neck cSCC. Both factors were implicated with poorer responses to immune checkpoint inhibition, and the latter with poorer survival. CONCLUSIONS: We identified tumour and host immune factors that contribute to the disparate clinical behaviour of cSCC, with broad translational application, including prognostication, treatment prediction to current therapies and the identification of novel anticancer therapy approaches in cSCC.
引用
- Thai AA, Young RJ, Bressel M, et al. Comprehensive profiling identifies tumour and immune microenvironmental differences in clinical subsets of cutaneous squamous cell carcinoma. Br J Dermatol. 2023. PMID: 37470440. doi:10.1093/bjd/ljad250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。